Clinical Trial Update: Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC) [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating a combination of alpelisib, an iNOS inhibitor, and nab-paclitaxel in HER2-negative metaplastic breast cancer, with patient recruitmen…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Metaplastic Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Alpelisib (alpelisib)
• Nab-paclitaxel (paclitaxel protein-bound)
• iNOS inhibitor

Snippet

Sponsor: The Methodist Hospital Research Institute | Conditions: HER2-negative Breast Cancer, Metastatic Breast Cancer | Phase 2 | Status: RECRUITING